Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Jun;21(6):636-41.
doi: 10.1111/j.1525-1497.2006.00468.x.

Correlates of use of antifracture therapy in older women with low bone mineral density

Kathryn M Ryder  1 , Ronald I Shorr, Frances A Tylavsky, Andrew J Bush, Douglas C Bauer, Eleanor M Simonsick, Elsa S Strotmeyer, Tamara B Harris; Health ABC Study
Affiliations
Comparative Study

Correlates of use of antifracture therapy in older women with low bone mineral density

Kathryn M Ryder et al. J Gen Intern Med. 2006 Jun.

Abstract

Background: Guidelines exist for treatment of low bone mineral density (BMD). Little is known about patient characteristics associated with use of treatment.

Objectives: To determine patient-related correlates of medication use following screening dual x-ray absorptiometry (DXA) of older adults.

Design: Secondary analysis of a prospective cohort study.

Setting: Pittsburgh, PA and Memphis, TN.

Participants: Community-dwelling women between the ages 70 and 79 years enrolled in the Health, Aging, and Body Composition (Health ABC) Study.

Measurements: Risk factors for fracture and BMD of the hip were assessed at baseline. Patients and their community physicians were supplied the results of the DXA scan. Prescription and over-the-counter medication use was collected at annual exams for 2 years.

Results: Of 1,584 women enrolled in Health ABC, 378 had an indication for antifracture therapy and were not receiving such treatment at baseline. By the second annual follow-up examination, prescription antiresorptive medication was reported in 49 (13.0%), whereas 65 (17.2%) received calcium and/or vitamin D supplementation. In adjusted models, the strongest predictor for use of any antifracture medicine was presence of osteoporosis [vs osteopenia, odds ratio (OR), 2.9 (1.7 to 4.7)], white race [OR, 2.6 (1.5 to 4.8)], and receipt of the flu shot [OR, 2.2 (1.3 to 3.8)]. Neither a history of falls nor prior fracture was associated with use of antifracture medications.

Conclusion: Even when physicians of study participants were provided with DXA scan results, 70% of older high-functioning women with an indication for therapy did not start or remain on an antifracture therapy. Substantial room for improvement exists in fracture prevention following a diagnosis of low BMD-especially among women with a history of falls, prior fractures, and among black women.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Women included in the current secondary analysis of the Health, Aging and Body Composition cohort. Of 378 women with an National Osteoporosis Foundation indication for antifracture therapy and not on therapy at baseline, only 30% initiated some form of treatment by 2 years. AFT, antifracture therapy; DXA, dual x-ray absorptiometry.
See this image and copyright information in PMC

References

    1. Looker AC, Johnston CC, Jr, Wahner HW, et al. Prevalence of low femoral bone density in older US women from NHANES III. J Bone Miner Res. 1995;10:796–802. - PubMed
    1. Kanis JA, Johnell O, Oden A, Dawson A, De Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int. 2001;12:989–95. - PubMed
    1. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118–24. - PubMed
    1. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–82. - PubMed
    1. Watts NB, Josse RG, Hamdy RC, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2003;88:542–9. - PubMed

Publication types